pubmed.ncbi.nlm.nih.gov

Methotrexate for maintenance of remission in Crohn's disease - PubMed

️Thu Jan 01 2009

Review

Methotrexate for maintenance of remission in Crohn's disease

Vishal Patel et al. Cochrane Database Syst Rev. 2009.

Update in

Methotrexate for maintenance of remission in Crohn's disease.
Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N. Patel V, et al. Cochrane Database Syst Rev. 2014 Aug 26;2014(8):CD006884. doi: 10.1002/14651858.CD006884.pub3. Cochrane Database Syst Rev. 2014. PMID: 25157445 Free PMC article. Review.

Abstract

Background: Safe and effective long-term treatments that reduce the need for corticosteroids are needed for Crohn's disease. Although purine antimetabolites are moderately effective for maintenance of remission patients often relapse despite treatment with these agents. Methotrexate may provide a safe and effective alternative to more expensive maintenance treatment with TNF-alpha antagonists.

Objectives: To conduct a systematic review of randomized trials examining the efficacy and safety of methotrexate for maintenance of remission in Crohn's disease.

Search strategy: The Cochrane Central Register of Controlled Trials (CENTRAL) Issue 2, 2009, PUBMED (1966 to April 2009), EMBASE (1984 to April 2009), DDW abstracts (1980 to 2008) and the Cochrane IBD/FBD Specialized Trials Register were searched. Study references and review papers were also searched for additional trials.

Selection criteria: Randomised controlled trials (RCTs) that compared methotrexate to placebo or any other active intervention for maintenance of remission in Crohn's disease were eligible for inclusion.

Data collection and analysis: Data extraction and assessment of methodological quality of included studies were independently performed by each author. The main outcome measure was the proportion of patients maintaining clinical remission as defined by the studies and expressed as a percentage of the total number of patients randomized (intention to treat analysis). Pooled odds ratios and 95% confidence intervals were calculated for dichotomous outcomes.

Main results: Three studies were included in the review. A pooled analysis (n = 98) including one high quality trail (n = 76) showed that intramuscular methotrexate (15 mg/week) was significantly more effective than placebo for maintenance of remission in Crohn's disease (OR 3.11; 95% CI 1.31 to 7.41; P = 0.01). The number needed to treat to prevent one relapse was 4. A pooled analysis of two small studies (n = 50) showed no difference between methotrexate and 6-MP for maintenance of remission (OR 2.63; 95% CI 0.74 to 9.37; P = 0.14). Adverse events were generally mild in nature and resolved upon discontinuation or with folic acid supplementation. Common adverse events included nausea and vomiting, symptoms of a cold, abdominal pain, headache, joint pain or arthralgia, and fatigue.

Authors' conclusions: Intramuscular methotrexate at a dose of 15 mg/week is safe and effective for maintenance of remission in Crohn's disease. Oral methotrexate (12.5 to 15 mg/week) does not appear to be effective for maintenance of remission in Crohn's disease.

PubMed Disclaimer

Cited by

Current therapy of pediatric Crohn's disease.
Lahad A, Weiss B. Lahad A, et al. World J Gastrointest Pathophysiol. 2015 May 15;6(2):33-42. doi: 10.4291/wjgp.v6.i2.33. World J Gastrointest Pathophysiol. 2015. PMID: 25977836 Free PMC article. Review.
Efficacy of methotrexate in ulcerative colitis: failure or promise.
Herfarth HH, Osterman MT, Isaacs KL, Lewis JD, Sands BE. Herfarth HH, et al. Inflamm Bowel Dis. 2010 Aug;16(8):1421-30. doi: 10.1002/ibd.21246. Inflamm Bowel Dis. 2010. PMID: 20186931 Free PMC article. Review.
Methotrexate in inflammatory bowel disease: A primer for gastroenterologists.
AlAmeel T, Al Sulais E, Raine T. AlAmeel T, et al. Saudi J Gastroenterol. 2022 Jul-Aug;28(4):250-260. doi: 10.4103/sjg.sjg_496_21. Saudi J Gastroenterol. 2022. PMID: 35042318 Free PMC article. Review.
Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.
Vasudevan A, Raghunath A, Anthony S, Scanlon C, Sparrow MP, Gibson PR, van Langenberg DR. Vasudevan A, et al. Dig Dis Sci. 2019 Jun;64(6):1622-1631. doi: 10.1007/s10620-018-5422-8. Epub 2018 Dec 17. Dig Dis Sci. 2019. PMID: 30560332
Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease.
Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F. Sansone S, et al. World J Gastroenterol. 2014 Apr 7;20(13):3516-24. doi: 10.3748/wjg.v20.i13.3516. World J Gastroenterol. 2014. PMID: 24707134 Free PMC article. Review.

Methotrexate for maintenance of remission in Crohn's disease - PubMed